Journal of Immunology Research / 2019 / Article / Tab 3

Research Article

Immunomodulatory Effects of Combination Therapy with Bushen Formula plus Entecavir for Chronic Hepatitis B Patients

Table 3

Baseline characteristics of CHB patients and normal controls .

GroupSexAge (years)ALT (U/l)HBV DNA (log10IU/ml)HBeAg (log10COI)HBsAg (log10IU/ml)

Normal controls6525.0 (25.0–26.0)17.5 (10.6–35.8)N.A.N.A.N.A.
Treatment-naïve patients26641.0 (35.3–48.5)57.5 (41.5–96.0)6.63 (5.13–7.48)2.28 (0.00–2.88)3.85 (3.31–4.01)
Patients with partial virological response to ETV21332.0 (28.3–37.5)34.0 (23.3–47.0)N.A.1.98 (0.23–3.09)3.85 (3.41–4.14)

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.